Aflac Announces Participation in TOMADACHI Initiative

Wed Jan 23, 2013 9:26am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link

Aflac Supports International Training Program for Pediatric Cancer Specialists
COLUMBUS, Ga.,  Jan. 23, 2013  /PRNewswire/ -- Aflac, the number one provider of
supplemental insurance in  the United States  and  Japan, announced its
participation in the TOMADACHI Initiative, a joint enterprise led by the United
States Government and the U.S.-Japan Council.  TOMADACHI is a public-private
partnership that invests in the next generation of Japanese and Americans in
ways that strengthen relationships between  the United States  and  Japan  over
the long-term.

The pediatric specialist program will lay the foundation for broader
understanding of research and treatment protocols for childhood cancer, and
enhance communication and cooperation between U.S. and  Japan  cancer
specialists. Beginning in  June 2013,  Japan-based pediatric cancer specialists
will come to the Aflac Cancer and Blood Disorders Center of Children's
Healthcare in  Atlanta, Georgia  to observe and share best practices related to
the care and treatment of children with cancer.  

"Aflac, our employees, and sales agents are committed to funding initiatives
that will help promote excellent care and help find a cure for childhood
cancer," said Aflac Chairman and CEO,  Dan Amos. "We are honored to participate
in this initiative, as we believe that the exchange of ideas will help improve
the standard of care for children fighting cancer."

Dr.  William G. Woods, Director of the Aflac Cancer Center, commented, "We are
very excited about the TOMODACHI-Aflac Scholarship Program, and believe that it
will help enhance the training of Japanese pediatric oncologists in clinical
care as well as research. We want to improve the lives of the brave children
battling cancer in  Japan, and their families who support them. We are also
confident that the program will further strengthen the friendship between Japan
and  the United States."

About Aflac

About Aflac When a policyholder gets sick or hurt, Aflac pays cash benefits
fast. For more than 58 years, Aflac insurance policies have given policyholders
the opportunity to focus on recovery, not financial stress. In  the United
States, Aflac is the number one provider of guaranteed-renewable insurance. In 
Japan, Aflac is the number one life insurance company in terms of individual
policies in force. Aflac individual and group insurance products provide
protection to more than 50 million people worldwide. For six consecutive years,
Aflac has been recognized by Ethisphere magazine as one of the World's Most
Ethical Companies. In 2013, FORTUNE magazine recognized Aflac as one of the 100
Best Companies to Work For in America for the 15th consecutive year. Also,
FORTUNE magazine included Aflac on its list of Most Admired Companies for the
11th time in 2012. Aflac Incorporated is a Fortune 500 company listed on the New
York Stock Exchange under the symbol AFL. To find out more about Aflac, visit  or  


TOMODACHI is a public-private partnership, led by the United States Government
and the U.S.-Japan Council and supported by the Japanese Government, that
supports  Japan's recovery from the Great East Japan Earthquake and invests in
the next generation of Japanese and Americans in ways that strengthen cultural
and economic ties and deepen the friendship between  the United States  and 
Japan  over the long-term.


 Media Contacts:      Analyst and Investor Contact:  
 Laura Kane           Robin Y. Wilkey                
 Aflac Incorporated   Aflac Incorporated             
 706.596.3493         1.800.235.2667                 
 706.593.0786 (cell)  Fax: 706.324.6330                    
 Jon A. Sullivan                                     
 Aflac Incorporated                                  
 706.573.7610 (cell)                                                          


Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.